Viewing Study NCT07211958

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 12:22 AM
Ignite Modification Date: 2025-12-25 @ 10:27 PM
Study NCT ID: NCT07211958
Status: RECRUITING
Last Update Posted: 2025-12-08
First Post: 2025-09-30
Is NOT Gene Therapy: False
Has Adverse Events: False
Brief Title: Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation
Sponsor: Syndax Pharmaceuticals
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Acute Myeloid Leukemias View
Keywords:

Keywords

Keyword Brief Keyword Text View
None SNDX-5613 View
None Nucleophosmin 1 View
None NPM1 View
None Acute Myeloid Leukemias View
None AML View
None Revumenib View
None Newly diagnosed AML View